Hantz Financial Services Inc. Sells 300,149 Shares of Pfizer Inc. $PFE

Hantz Financial Services Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 60.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 194,599 shares of the biopharmaceutical company’s stock after selling 300,149 shares during the quarter. Hantz Financial Services Inc.’s holdings in Pfizer were worth $4,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after acquiring an additional 10,198,330 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Pfizer by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after purchasing an additional 1,820,634 shares in the last quarter. Norges Bank purchased a new position in shares of Pfizer in the second quarter worth $2,270,157,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Pfizer by 2.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after purchasing an additional 1,135,457 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of Pfizer by 2.0% during the second quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock valued at $1,172,980,000 after buying an additional 950,239 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. UBS Group assumed coverage on shares of Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. Finally, Zacks Research downgraded Pfizer from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.06.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat — Pfizer reported stronger‑than‑expected Q4 revenue and adjusted EPS, which underpinned the rally and reassures investors that legacy drugs (like Eliquis) are offsetting COVID declines. Reuters: Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: GLP‑1 mid‑stage success — topline VESPER‑3 data for MET‑097i (monthly injectable) showed up to ~12.3% placebo‑adjusted weight loss and maintained weight loss after switching from weekly to monthly dosing, giving Pfizer a credible entrant in the high‑growth obesity market. Reuters: Pfizer’s experimental drug shows up to 12.3% weight loss
• Positive Sentiment: Longer‑term catalysts — analysts and commentators highlight Pfizer’s expanded oncology portfolio (including Seagen assets) and AI partnerships as multi‑year growth drivers that could meaningfully re‑rate the stock if late‑stage trials succeed. MarketBeat: Pfizer earnings & pipeline analysis
• Neutral Sentiment: Analyst stance is cautious — major firms (Goldman, Citi and others) are largely Neutral/Hold with price targets near the current level, reflecting upside from the pipeline but offset by near‑term headwinds. InsiderMonkey: Goldman Sachs maintains Neutral on Pfizer TipRanks: Citi Hold commentary
• Negative Sentiment: Guidance and margin pressure — Pfizer reiterated FY‑2026 guidance that implies EPS of ~$2.80–3.00 (around or slightly below consensus) and flagged near‑term profit declines, which keeps investors cautious on 2026 growth and margins. BusinessWire: Pfizer reaffirms 2026 guidance
• Negative Sentiment: Structural revenue headwinds — declining COVID product sales, patent‑cliff impacts and an expected ~$1.5B hit in coming periods were cited by analysts as reasons the stock can lag despite beats. FT: vaccines and patent pressures weigh on sales
• Negative Sentiment: Mixed investor reaction to obesity data — some coverage flagged safety/signal questions and that Pfizer’s monthly dosing may still face tough competition from established GLP‑1 leaders (Lilly, Novo); that uncertainty contributed to earlier share weakness. MSN: mixed response to weight‑loss data
• Negative Sentiment: Program shifts — Pfizer and partners have paused certain modRNA shingles ambitions, showing the company is re‑prioritizing pipeline choices; such changes can be seen as conservative but remove near‑term optionality. TipRanks: Pfizer/BioNTech pause modRNA shingles ambitions

Pfizer Stock Up 4.1%

PFE opened at $26.83 on Thursday. The firm’s 50 day simple moving average is $25.57 and its two-hundred day simple moving average is $25.07. The company has a market capitalization of $152.55 billion, a PE ratio of 19.73 and a beta of 0.47. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period in the prior year, the business posted $0.63 EPS. Pfizer’s revenue was down 1.2% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.